Monitor future earnings reports for any mention of revenue contribution from the methadone launch. Given the OTC listing and niche market, impact may be limited unless Elite captures significant share. Watch for competitive responses from existing generic manufacturers.
Price Chart
Executive Summary
Elite Pharmaceuticals announced the commercial launch of its generic version of methadone hydrochloride 5 mg and 10 mg tablets, marketed under the Elite Laboratories, Inc. label. Based on IQVIA data, the combined annual retail sales for brand and generic methadone tablets were approximately $22 million in 2025.
Key Facts
- Elite Pharmaceuticals launched its generic methadone hydrochloride 5 mg and 10 mg tablets.
- The product is marketed under the Elite Laboratories, Inc. label.
- Methadone is indicated for severe pain management and opioid addiction treatment.
- Total annual retail sales (brand + generic) for methadone tablets were $22 million in 2025, per IQVIA data.
- No financial projections, revenue guidance, or market share estimates were provided.
Financial Impact
Potential access to a $22 million annual market, though Elite's expected revenue contribution is undisclosed and likely incremental.
Risk Factors
- High competition in the generic pharmaceutical space may limit pricing power and market share gains.
- No financial guidance was provided, so revenue impact is uncertain.
- Company operates on the OTC market, which may limit investor visibility and liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-014813 |
| Exhibit: ex99-1.htm | 0001493152-26-014813 |
| Document: 0001493152-26-014813-index-headers.html | 0001493152-26-014813 |
| Document: 0001493152-26-014813-index.html | 0001493152-26-014813 |
| Document: 0001493152-26-014813.txt | 0001493152-26-014813 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 10, 2026 10w ago | 8-K | $0.3600 | awaiting T+60 | — | $0.2371 (−34.14%) |
Jun 29, 2026 16w ago | 8-K | $0.3700 $0.2470 | ▼ −33.24% | ▼ −37.08% | $0.2371 (−35.92%) |
Jun 15, 2026 19w ago | 8-K | $0.3700 $0.2599 | ▼ −29.76% | ▼ −31.02% | $0.2371 (−35.92%) |
Jun 1, 2026 21w ago | 8-K | $0.3600 $0.2827 | ▼ −21.47% | ▼ −22.70% | $0.2371 (−34.14%) |
Apr 2, 2026 29w ago | 8-K | $0.3800 $0.3651 | ▼ −3.92% | ▼ −18.08% | $0.2371 (−37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers